Related Experiment Videos
[Balanced beta--alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension]
M Perocchio1, G Gigli, M Barra
1Servizio di Cardiologia, UTIC, Ospedale di Rapallo, Genova.
Abstract:
The search for the ideal antihypertensive drug is ongoing. Carvedilol is a new beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade. Twenty patients with mild to moderate essential hypertension and previous intolerance and side effects to other antihypertensive drugs were studied. After initial baseline assessment, patients received 25 mg carvedilol orally q.d. The treatment lasted 60 days. In our study carvedilol was well tolerated and no important side effect was recorded. Blood pressure decreased significantly to normal values, without orthostatic blood pressure decreases. Heart rate decreased significantly too, but no significant bradycardia was induced. No negative effects on serum lipids and no clinical evidence of increase in peripheral resistance were observed. Ventricular arrhythmia on Holter monitoring were significantly reduced after treatment with carvedilol.
Insights
Carvedilol effectively lowers blood pressure and reduces ventricular arrhythmias in patients with essential hypertension. This new antihypertensive drug was well-tolerated, showing no significant side effects during the 60-day study.
Area of Science:
- Cardiology
- Pharmacology
Background:
- The development of effective antihypertensive medications is crucial for managing cardiovascular health.
- Carvedilol, a novel beta-adrenoceptor antagonist, offers potential benefits through combined alpha- and beta-adrenergic blockade.
- Essential hypertension management often faces challenges with patient intolerance to existing drugs.
Purpose of the Study:
- To evaluate the efficacy and tolerability of carvedilol in patients with mild to moderate essential hypertension.
- To assess the impact of carvedilol on blood pressure, heart rate, and ventricular arrhythmias.
- To determine the safety profile of carvedilol, including effects on serum lipids and peripheral resistance.
Main Methods:
- A 60-day open-label study involving twenty patients with essential hypertension.
- Patients received a daily oral dose of 25 mg carvedilol.
- Outcomes were assessed through blood pressure monitoring, heart rate evaluation, Holter monitoring for arrhythmias, and assessment of side effects.
Main Results:
- Carvedilol significantly reduced blood pressure to normal levels without causing orthostatic hypotension.
- A significant decrease in heart rate was observed, without inducing significant bradycardia.
- Ventricular arrhythmias were significantly reduced, and the drug was well-tolerated with no major side effects or negative impact on serum lipids or peripheral resistance.
Conclusions:
- Carvedilol is a well-tolerated and effective antihypertensive agent for patients with mild to moderate essential hypertension.
- The drug demonstrates significant efficacy in lowering blood pressure and reducing ventricular arrhythmias.
- Carvedilol presents a promising therapeutic option for hypertensive patients intolerant to other medications.